[predictive Factors For Height Gain In Idiopathic Central Precocious Puberty Treated With Gnrh Analogues].

dc.creatorBenetti-Pinto, Cristina Laguna
dc.creatorCamargo, Luciana Bandeira Nunes
dc.creatorMagna, Luis Alberto
dc.creatorGarmes, Heraldo Mendes
dc.creatorPetta, Carlos Alberto
dc.date2008-Dec
dc.date2015-11-27T13:13:27Z
dc.date2015-11-27T13:13:27Z
dc.date.accessioned2018-03-29T01:07:59Z
dc.date.available2018-03-29T01:07:59Z
dc.identifierRevista Brasileira De Ginecologia E Obstetrícia : Revista Da Federação Brasileira Das Sociedades De Ginecologia E Obstetrícia. v. 30, n. 12, p. 609-13, 2008-Dec.
dc.identifier1806-9339
dc.identifier
dc.identifierhttp://www.ncbi.nlm.nih.gov/pubmed/19219342
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/198101
dc.identifier19219342
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1298334
dc.descriptionto evaluate predictive factors of response to GnRHa treatment in girls with idiopathic central precocious puberty. a retrospective cohort study was conducted involving 33 girls diagnosed with idiopathic central precocious puberty and treated with GnRHa. The following independent variables were assessed: age at the beginning of therapy and at the onset of symptoms, time elapsed since the appearance of pubertal characteristics and the beginning of treatment, bone age, bone age advance, duration of GnRHa treatment, actual height and Z-score, predicted height and Z-score and hormone measurements of FSH and LH after GnRH stimulation, which were correlated with gain in height as a dependent variable at treatment discontinuation, calculated by the difference between the predicted height at the end and beginning of treatment. For statistical analysis, Pearson's linear correlation was used, in addition to multiple linear regression analysis. the mean age at the beginning of treatment was 7.8+/-1.3 years, with a mean bone age of 10.1+/-1.6 years. Bone age advance was 2.3+/-1.1 years and was controlled during the treatment period. Gain in predicted height was 2.5+/-1.3cm. It was positively correlated with time elapsed since the beginning of symptoms and the beginning of treatment and with bone age advance, while negatively correlated with the Z-score of height at the beginning of treatment and predicted height at the beginning of treatment, and the latter was the main factor determining gain from treatment. girls who had the most significant compromise of predicted adult height, as detected by a larger deviation from the population (Z-score) and the most considerable advance in bone age, received benefit from GnRHa therapy, and they must not be excluded from the group to be treated.
dc.description30
dc.description609-13
dc.languagepor
dc.relationRevista Brasileira De Ginecologia E Obstetrícia : Revista Da Federação Brasileira Das Sociedades De Ginecologia E Obstetrícia
dc.relationRev Bras Ginecol Obstet
dc.rightsaberto
dc.rights
dc.sourcePubMed
dc.subjectBody Height
dc.subjectChild
dc.subjectCohort Studies
dc.subjectFemale
dc.subjectGonadotropin-releasing Hormone
dc.subjectHumans
dc.subjectLeuprolide
dc.subjectPrognosis
dc.subjectPuberty, Precocious
dc.subjectRetrospective Studies
dc.title[predictive Factors For Height Gain In Idiopathic Central Precocious Puberty Treated With Gnrh Analogues].
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución